![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Paclitaxel-induced peripheral neuropathic pain (PIPNP) is a major therapy- and dose-limiting side effect that is extremely laborious to treat. Resveratrol (Res), with a structure name of 3,5,40-trihydroxystilbene, is a kind of natural polyphenolic chemical with plenty of useful characteristics such as anti-inflammatory, and anti-oxidative stress. However, the impact of Res on PIPNP remains unclear. Therefore, the current study intends to examine the analgesic effect of Res on PIPNP. In the present study, the results revealed that Res could effectively prevent the development of paclitaxel-induced PIPNP in a dose-dependent manner when repeated doses of Res were given during PIPNP induction. This prophylactic effect of Res was involved in inhibited paclitaxel-induced up-regulation of TRPV1 instead of TRPA1 in the dorsal root ganglia. Furthermore, the inhibition of TRPV1 up-regulation by Res may be involved in a phosphorylation of ERK mechanism. In summary, we conclude that Res plays an intriguing role in the prevention of PIPNP and thus may work as a therapeutic compound for treating and preventing PIPNP.
KEYWORDS:
Acknowledgements
This work was supported by grants from National Natural Science Foundation of Sun Yat-sen University [Grant number 201901245].
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data are not available.